Asundexian Investor Webinar August 2022

At this event, results from the PACIFIC study program that included three Phase II studies examining the use of the FXI(a) inhibitor asundexian vs. apixaban in patients with atrial fibrillation (PACIFIC-AF), the use of asundexian in combination with antiplatelet therapy vs. antiplatelet therapy alone in patients at risk to develop a secondary ischemic stroke (PACIFIC-Stroke) and the use of asundexian in combination with dual antiplatelet therapy vs. dual antiplatelet therapy alone in patients with an acute myocardial infarction (PACIFIC-AMI), will be presented. Presenters will be Manesh R. Patel, M.D., Duke Clinical Research Institute, Duke University, USA, Ashkan Shoamanesh, M.D., McMaster University in Hamilton, Canada, and John Eikelboom, M.D., McMaster University in Hamilton, Canada, respectively.

Christian Rommel, Head of R&D, Bayer Pharmaceuticals, will put the role of asundexian into the context of today’s treatment landscape in cardiovascular diseases and will illustrate its potential as a new and innovative advanced therapeutic option to address still high unmet medical needs. Finally, Christoph Koenen, Head of Clinical Development & Operations, Bayer Pharmaceuticals, will summarize the PACIFIC study results and give an update on the further development program for asundexian.

The presentations will be followed by a Q&A session which will also be joined by Stefan Oelrich, President of Bayer’s Pharmaceuticals Division and Member of the Board of Management, Bayer AG.

Monday, August 29, 2022